Given the large stake in the stock by institutions, Nektar Therapeutics' stock price might be vulnerable to their trading decisions The top 11 shareholders own 52% of the company Every investor in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback